Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Travis Perkins appoints SIG's Gavin Slark as new CEO

(Sharecast News) - Builders' merchant Travis Perkins said on Friday that it has appointed Gavin Slark - the current chief executive of construction group SIG - as its new CEO with effect no later than 1 January 2026. Travis Perkins said Slark is a highly experienced public company CEO, with "significant" experience of the building materials and merchanting industry. He has been CEO of SIG since 2023, prior to which he was CEO of Grafton Group between 2011 and the end of 2022.

Between 2006 and 2011, Slark was CEO of The BSS Group before its acquisition by Travis Perkins.

Chair Geoff Drabble said: "The board and I are delighted that Gavin has agreed to join us. We are all very much looking forward to working with him. Gavin brings with him unrivalled experience of the sector in addition to a long pedigree as a CEO of significant public companies.

"Gavin is well placed to continue the work we have started to refocus and change the way we operate in order to better serve our customers and work effectively with our suppliers, as well as engage and motivate our teams."

SIG said Slark will stay on as CEO for a transitionary period, until no later than 31 December 2025.

A process to identify a successor is now underway, it said.

SIG chairman Andrew Allner said: "The board looks forward to continuing working with Gavin until his departure. He has steered the group well through a difficult period in the European construction industry.

"He will leave in place strong and experienced leaders in each of our businesses, all operating under SIG's well established devolved structure."

At 0830 BST, TPK shares were up 4.6% at 610p, while SIG was 7.8% lower at 16.60p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.